|
As gore was unable to determine which device was involved in the event if any; additional device(s) implanted include: tgu404015/10254765, udi: (b)(4).Patient medications include but are not limited to: lebetalol injection, phytonadione injection, oxygen nasal cannula, lactated ringers, esmolol infusion, magnesium sulfate iv piggy back.According to the instructions for use (ifu) for the gore® tag® thoracic endoprosthesis; adverse events that may occur include, but are not limited to include: endoleak a review of the manufacturing records for the device(s) verified that the lot(s) met all pre-release specifications.
|
|
On (b)(6) 2012, this patient underwent endovascular treatment for a thoracic aortic aneurysm and two conformable gore® tag® thoracic endoprostheses were implanted.The patient tolerated the procedure.On (b)(6) 2018, the patient underwent reintervention for a distal type i endoleak caused by degeneration of the distal descending thoracic aorta.Two additional conformable gore® tag® thoracic endoprostheses were implanted, to extend coverage both proximally and distally.The patient tolerated the procedure and the endoleak was resolved.No aneurysm enlargement was reported.
|